Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.
Int J Pharm. 2013 Aug 16;452(1-2):220-6. doi: 10.1016/j.ijpharm.2013.05.022. Epub 2013 May 18.
The present study aimed to develop novel solid dispersion (SD) of tranilast (TL) using amphiphilic block copolymer, poly[MPC-co-BMA] (pMB), to improve the dissolution and pharmacokinetic behavior of TL. pMB-based SD of TL (pMB-SD/TL) with drug loading of 50% (w/w) was prepared by wet-mill technology, and the physicochemical properties were characterized in terms of morphology, crystallinity, dissolution, and hygroscopicity. Powder X-ray diffraction and polarized light microscopic experiments demonstrated high crystallinity of TL in pMB-SD/TL. The pMB-SD/TL exhibited immediate micellization when introduced to aqueous media, forming fine droplets with a mean diameter of ca. 122 nm. There was marked improvement in the dissolution behavior for the pMB-SD/TL even under acidic conditions, although the supersaturated TL concentration gradually decreased. NMR analyses demonstrated interaction between TL and pMB, as evidenced by the chemical shift drifting and line broadening. Pharmacokinetic behaviors of orally dosed TL formulations were evaluated in rats using UPLC/ESI-MS. After oral administration of pMB-SD/TL (10mg TL/kg) in rats, enhanced TL exposure was observed with increases of Cmax and AUC by 125- and 52-fold, respectively, compared with those of crystalline TL. From these findings, pMB-based SD formulation approach might be an efficacious approach for enhancing the therapeutic potential of TL.
本研究旨在开发一种使用两亲嵌段共聚物聚[MPC-co-BMA](pMB)的新型曲尼司特(TL)固体分散体(SD),以改善 TL 的溶解和药代动力学行为。采用湿磨技术制备载药量为 50%(w/w)的 pMB 为基础的 TL SD(pMB-SD/TL),并从形态、结晶度、溶解和吸湿性等方面对其理化性质进行了表征。粉末 X 射线衍射和偏光显微镜实验表明 pMB-SD/TL 中 TL 的结晶度很高。当 pMB-SD/TL 引入水介质时,会立即胶束化,形成平均直径约为 122nm 的细小液滴。即使在酸性条件下,pMB-SD/TL 的溶解行为也有明显改善,尽管过饱和 TL 浓度逐渐降低。NMR 分析表明 TL 与 pMB 之间存在相互作用,表现为化学位移漂移和谱线增宽。采用 UPLC/ESI-MS 法在大鼠体内评价口服 TL 制剂的药代动力学行为。与结晶 TL 相比,大鼠口服 pMB-SD/TL(10mg TL/kg)后,TL 的 Cmax 和 AUC 分别增加了 125 倍和 52 倍,表明 TL 暴露增加。从这些发现来看,基于 pMB 的 SD 制剂方法可能是增强 TL 治疗潜力的有效方法。